https://www.statcounter.com/counter/counter.js
Web Analytics
Home » Posts tagged with » George D. Yancopoulos
Praluent bags EC approval to reduce risk of CV events in patients with ASCD

Praluent bags EC approval to reduce risk of CV events in patients with ASCD

Regeneron Pharmaceuticals and Sanofi have secured approval for Praluent (alirocumab) for a new indication from the European Commission (EC), which is for the reduction of cardiovascular risk in adults with established atherosclerotic CV disease (ASCD) by reducing low-density lipoprotein cholesterol (LDL-C) levels as an adjunct to correct other risk factors. Atherosclerotic CV Disease is defined […]

Sanofi, Regeneron report Dupixent FDA approval for asthma

Dupixent FDA approval : Dupixent (dupilumab), an eczema drug the co-developed by Sanofi and Regeneron Pharmaceuticals, has been approved by the US Food and Drug Administration as an add-on maintenance therapy for two forms of asthma. Dupixent FDA Approval The new Dupixent FDA approval is for treating patients with moderate-to-severe asthma aged 12 years and older […]

Continue reading …
Regeneron secures updated label approval from FDA for EYLEA in wet-AMD

The US Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) by Regeneron Pharmaceuticals for EYLEA (aflibercept) Injection in patients with wet age-related macular degeneration (wet AMD). Regeneron Pharmaceuticals said that the sBLA is supported by second-year data recorded from the phase 3 VIEW 1 and 2 trials in which patients […]

Continue reading …
Teva, Regeneron report positive data for fasinumab in phase 3 osteoarthritis trial

Teva Pharmaceutical Industries and Regeneron Pharmaceuticals said that a phase 3 study evaluating nerve growth factor (NGF) antibody fasinumab in patients with chronic pain from osteoarthritis (OA) of the knee or hip met both co-primary endpoints and all key secondary endpoints. According to the partners, fasinumab-treated patients had faced significantly less pain and had considerably […]

Continue reading …